Voyager Therapeutics, Inc. (VYGR)

Market Cap	205.37M
Revenue (ttm)	80.00M
Net Income (ttm)	-65.00M
Shares Out	55.21M
EPS (ttm)	-1.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	340,887
Open	3.810
Previous Close	3.910
Day's Range	3.655 - 3.900
52-Week Range	3.560 - 10.660
Beta	0.99
Analysts	Strong Buy
Price Target	15.75 (+322.82%)
Earnings Date	Mar 11, 2025

About VYGR

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company’s lead clinical candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer’s disease. Its product pipeline includes VY1706, tau silencing gene therapy in preclinical trial for treatment of alzheimer’s disease; SOD1 silencing gene therapy program for the treatment of ALS in preclinical trial; and vectorized anti-amyloid antibody early research program for the treatment of AD in preclinical tr...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 11, 2015
• Employees: 172
• Stock Exchange: NASDAQ
• Ticker Symbol: VYGR
• Website: https://www.voyagertherapeutics.com

Analyst Forecast

According to 10 analysts, the average rating for VYGR stock is "Strong Buy." The 12-month stock price forecast is $15.75, which is an increase of 322.82% from the latest price.

Price Target

$15.75

(322.82% upside)

Analyst Consensus: Strong Buy